Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors
Hodgkin lymphoma is a highly curable malignancy in early and advanced stages. Most patients are diagnosed in their teens or twenties and are expected to live decades beyond their treatment. Therefore, the toxicity of treatment must be balanced with the goal of cure. Thus, treatment has been refined...
Main Authors: | Pamela B Allen, Leo I Gordon |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2017-09-01
|
Series: | Clinical Medicine Insights: Oncology |
Online Access: | https://doi.org/10.1177/1179554917731072 |
Similar Items
-
Evolution of drug therapy for classical Hodgkin lymphoma
by: N. Y. Samaneva, et al.
Published: (2022-09-01) -
CAR-T Cell Therapy for Classical Hodgkin Lymphoma
by: Mikalai Katsin, et al.
Published: (2023-12-01) -
Prognostic Markers within the Tumour Microenvironment in Classical Hodgkin Lymphoma
by: Arina Martynchyk, et al.
Published: (2023-10-01) -
Genetics of classical Hodgkin Lymphoma
by: Gianluca Schiavoni, et al.
Published: (2018-06-01) -
Unraveling the Immune Microenvironment in Classic Hodgkin Lymphoma: Prognostic and Therapeutic Implications
by: Vasileios Georgoulis, et al.
Published: (2023-06-01)